Articolul precedent |
Articolul urmator |
328 2 |
Ultima descărcare din IBN: 2023-06-03 19:49 |
SM ISO690:2012 KRISHNA, Gouri Durga, SABEENA, Mohammed Suhail, SUNNY, Nevil Bastian, DANG, Kanishk, SASU, Dorian. A study on COLCORONA trial and its results. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 153. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 153-153 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. The COLCHICINE Coronavirus SARS-CoV2 trial (COLCORONA TRIAL) evaluates efficacy and safety of colchicine in adult patients, diagnosed with COVID-19 infection .The patients were not under immediate consideration for hospitalization and with atleast one high risk criteria. Objective of the study. To understand the efficiency and safety of colchicine as a treatment modality in patient population. Material and Methods. A systematic review of the COLCORNA trial conducted as a randomized,double-blind trial, placebo-controlled, multicenter investigator- initiated trial comparing colchicine(0.5mg twice daily for the first 3 days and then once daily for the 7days therafter)with placebo in a 1:1 ration, in non hospitalized COVID-19 patients . Results. Among the 4159 patients with PCR-confirmed, the primary endpoint occurred in 4.6% and 6.0% of patients in the colchicine and placebo groups, respectively (odds ratio, 0.75; 95% CI, 0.57 to 0.99; P=0.04). In these patients with PCR-confirmed COVID-19, the odds ratios were 0.75 (95% CI, 0.57 to 0.99) for hospitalization due to COVID-19, 0.50 (95% CI, 0.23 to 1.07) for mechanical ventilation, and 0.56 (95% CI, 0.19 to 1.66) for death. Serious adverse events were reported in 4.9% and 6.3% in the colchicine and placebo groups (P=0.05); pneumonia occurred in 2.9% and 4.1% of patients (P=0.02). Conclusion. Among non-hospitalized patients with COVID-19, colchicine reduces the composite rate of death or hospitalization. |
||||||
Cuvinte-cheie COLCORONA, colchicine, COVID-19, COLCORONA, colchicina, COVID-19 |
||||||
|